The clinical mutatome of core binding factor leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Core binding factor (CBF) leukemia, a subtype of acute myeloid leukemia (AML), arises from specific fusion genes (CBFB/MYH11, RUNX1/RUNX1T1) disrupting normal cell differentiation.
• Despite a generally favorable prognosis, a significant portion of CBF-AML patients are refractory to chemotherapy, suggesting the influence of additional genetic alterations.
• The spectrum and prognostic impact of these co-occurring mutations in CBF-AML remain incompletely understood.

Purpose of the Study:

• To comprehensively characterize the mutational landscape ('mutatome') in adult de novo CBF-AML.
• To identify novel mutations collaborating in leukemogenesis alongside CBF-rearrangements.
• To investigate the differential mutational profiles between CBFB/MYH11 and RUNX1/RUNX1T1 subtypes and their prognostic relevance.

Main Methods:

• Targeted sequencing of 129 genes in 292 adult CBF-AML patients.
• Analysis of mutation spectrum and correlation with specific fusion gene subtypes.
• Evaluation of prognostic relevance of identified mutations and clinical factors.

Main Results:

• Fundamental differences in mutation profiles were observed between CBFB/MYH11 and RUNX1/RUNX1T1 rearranged AML.
• Mutations in ASXL2, JAK2, JAK3, RAD21, TET2, and ZBTB7A were significantly associated with the RUNX1/RUNX1T1 subgroup.
• Novel recurrent mutations were identified in NFE2, MN1, HERC1, and ZFHX4, with prognostic significance also noted for KIT, SMC1A, and DHX15 mutations.

Conclusions:

• The study provides a comprehensive overview of the CBF-AML 'mutatome', highlighting subtype-specific genetic alterations.
• Identified mutations and clinical factors (age, nonprimary AML, Y-chromosome loss) are crucial for predicting patient outcomes.
• These findings support improved risk stratification and the development of targeted therapeutic strategies for CBF-AML.